Linda Peitzman, MD
Chief Medical Informatics Officer (CMIO)
Dr. Linda Peitzman brings over 25 years of experience in the areas of Healthcare IT applications software, informatics and clinical decision support offerings to HealthMyne. She has deep process expertise in EMR integration, quality improvement, codified medical terminologies, data integration and management, physician change management and many other areas of healthcare clinical workflow optimization. She is a Fellow of the American Academy of Family Physicians and a Diplomate of the American Board of Family Medicine. Linda also holds a Board Certification in Clinical Informatics and received her MD from the University of Minnesota.
John Pins
CFO
John is an operationally-focused executive with over 20 years of experience in healthcare technology finance. Over the course of his career, he has worked closely with operating teams on aggressive growth initiatives including strategic acquisitions, new product development, and global business and revenue expansion. John is a CPA and received his BA in Accounting from Iowa State University.
Career Highlights:
- 18 years at Wolters Kluwer; worked in a Public Accounting firm as his first job
- Vice President, Finance at Wolters Kluwer Health from 2006-2015. Reported to the CEO (AS)
- Vice President, Controller at $2B Blue Cross & Blue Shield of Kansas City prior to joining HealthMyne
Neal Miller, MBA
Vice President of Marketing
Neal has nearly 20 years of pharmaceutical and medical device marketing experience, including almost 14 years in radiation oncology. Before joining HealthMyne he was the Director of Marketing for Mobius Medical Systems, a startup firm that introduced a paradigm shift in patient plan and patient delivery QA to radiation therapy departments worldwide. Neal also held positions in marketing and product management at Standard Imaging and was an integral part of the marketing team at Bone Care International that launched Hectorol®, a vitamin D derivative used in the treatment of kidney disease.
Derek Cooper
VP of Customer Success
Derek is a highly skilled clinical and technical service leader with deep experience working in service implementation, integration and support for PACS and clinical decision support/informatics software solutions. He received his BS and MS in Computer Science from the University of Michigan (Ann Arbor).
Career Highlights:
- Director, Implementation at Roche Diagnostics: responsible for building the customer service team for Roche’s NAVIFY decision support portfolio, which includes a tumor conference module
- Director, Service and Support at Philips Healthcare – Healthcare Informatics. Led a large team responsible for the full-service life cycle of radiology and cardiology informatics solutions.
- Radiology IT Programmer/Analyst at Michigan State University and Froedert Hospital System (Milwaukee, WI)
John Kuelper, J.D., MBA
John Kuelper is a Managing Director at Ascension Ventures, a strategic venture capital and growth equity firm with over $800 million under management which invests in health IT, health services, medical devices and diagnostics on behalf of thirteen of the nation’s largest non-profit health systems. John is Founder and President of Qualia Holdings LLC, a platform for systems biology and software ventures. He has advised or worked for several investment firms (Adams Street Partners, Sterling Partners, Abundant Venture Partners), medical technology companies (Stereotaxis, Orpheden Therapeutics), and non-profits (The Kresge Foundation, the Blue Cross and Blue Shield Association). John began his career as a medical researcher studying computational neuroscience and medical robotics and has over fifteen years of experience as a commercial software developer. John earned JD and MBA degrees from the Northwestern University and a BA in cognitive neuroscience from Washington University in St. Louis. In 2014 he was elected to the Kauffman Fellows Society.
T. “Rock” Mackie, Ph.D.
Chairman
Rock is a Director of Medical Devices (part-time) at the Mortgridge Institute for Research in Madison and Emeritus Professor in the departments of Medical Physics, Human Oncology, and Engineering Physics at the UW-Madison. In 1997, Rock co-founded TomoTherapy Inc., which developed an innovative, integrated hardware/software system for accurate, image-guided radiation treatment delivery. TomoTherapy’s initial public offering in 2007 reached a peak market capitalization of over $1.2 B under Rock’s leadership as chairman of the board of directors. Prior to its sale to Accuray, TomoTherapy’s cumulative revenues exceeded $ 1 billion. In 1992, Rock co-founded Geometrics, a HCIT company which developed the PinnacleTM Radiation Treatment Planning (RTP) system, now marketed by Philips Medical Systems. From 1996 until 2012, Pinnacle generated over $350 M in revenues and achieved a 45+% global market share. Rock has a doctorate in Physics from the University of Alberta. He has more than 150 publications and over 30 inventions with issued US patents.
Milton Silva-Craig, J.D., MBA
Mr. Silva-Craig currently serves as the CEO of Q-Centrix, LLC. He has more than 20 years of business leadership experience in the healthcare and information technology industries and has demonstrated success in leading and managing high-growth businesses. Prior to Q-Centrix, Silva-Craig served as president of TransUnion’s healthcare business unit.
There, he developed and executed a strategic business plan focused on growing and repositioning TransUnion in the healthcare marketplace. His work resulted in an eight-fold increase in growth of the business unit. At Emageon Inc. (NASDAQ: EMAG), Silva-Craig led the company’s strategic direction and operations. He grew revenues from several hundred thousand dollars to more than $100 million annually and eventually led Emageon through its initial public offering. He was also president and CEO of Technology Solutions Company (NASDAQ: TSCC) and held executive positions at General Electric Medical Systems. Silva-Craig earned a J.D. from the University of Wisconsin-School of Law in Madison and obtained his M.B.A. and B.A. from the University of Wisconsin – Madison.
Scott Button, CFA, MBA
Scott is a Managing Director at Venture Investors, a leading provider of seed and early stage venture capital with over $250M in management. Scott joined the firm in 1996 and focuses on investment opportunities in medical devices, digital health, material sciences and information technology. He created the firm’s Venture Igniter program to encourage and support academic and student led start-ups.
Scott currently represents Venture Investors on the Board of Directors for HealthMyne, Silatronix, and NeuWave Medical. He serves on the Board of Advisors for the University of Wisconsin’s Chemistry Department, is a member of the Madison Development Corporation’s Debt Advisory Committee, is a MERLIN Mentor and a frequent guest lecturer at the UW Madison Business and Engineering schools. Prior to joining Venture Investors, Scott worked for McDonald’s Corporation and Rockwell Automation. He is a graduate of the University of Wisconsin-Madison (BS–Mechanical Engineering), The University of Chicago (MBA) and is a Chartered Financial Analyst (CFA).
Dan Malven, MBA
Dan has over two decades of operating and venture capital experience. Prior to 4490 Ventures, Dan was investing in early stage software companies at 1347 Ventures. Dan was also previously an executive at Walgreens and the co-founder of three software companies. Dan has a Master of Business Administration from the Kellogg School of Management at Northwestern University and a Bachelor of Sciences in Industrial Engineering from Purdue University.
David Gering, Ph.D.
Senior Scientist
David Gering is best known for developing the 3D Slicer as a master’s thesis project between the Surgical Planning Laboratory at Brigham and Women’s Hospital and the MIT Artificial Intelligence Laboratory. After many thousands of downloads, this free and open-source software package is a world renowned leader for medical image analysis and 3D visualization. In addition to his development of the 3D Slicer, his expertise in medical image segmentation and deformable registration have been honed during 12 years of experience with GE Healthcare and 4 years with TomoTherapy. He has been solving challenging problems throughout his career, as evidenced by 18 granted U.S. patents, as well as 40 scientific publications with a total of over 2,500 citations. David has a Ph.D. in Computer Science from MIT.
Roger Chylla, Ph.D.
Chief Technology Officer
Roger who cofounded HealthMyne in 2012 is an experienced technology entrepreneur who brings many years of successful commercial software design and development experience to HealthMyne’s team. Roger was a co-founder and CTO of Madison-based Ultravisual Medical Systems, prior to its merger with Emageon. At Ultravisual and later at Emageon, Roger was the senior engineering manager in charge of the medical imaging product, RadSuite, which by 2008 was installed at more than a hundred clinics nationwide. Roger was part of the executive team that led Emageon to a successful IPO in 2005 (NASDAQ: EMAG), generating over $500 M in cumulative revenues. The company reached a peak market capitalization of around $400 million prior to its sale to Amicas. Prior to forming UltraVisual, Roger was employed as senior software architect at ADAC Labs, where he served as design/development lead for new products. Roger has a Ph.D. in Biophysics from University of Illinois at Urbana Champaign.
Hao Wang, Ph.D.
VP of Systems Architecture
Hao is a co-founder of HealthMyne where he has been involved in designing and building the infrastructure for the HealthMyne QIDS platform. In addition, Hao is involved in dealing with various security and privacy aspects of the HealthMyne QIDS platform.
Prior to HealthMyne, Hao served as CTO of NovaShield where he led a team to design and develop a next-generation behavior-based anti-malware product from concept to commercialization. At NovaShield, Hao was also the Principal Investigator of an SBIR grant from the NSF that resulted in over $1M in grant funding for the company. Hao joined NovaShield in 2007 as director of research.
Hao has a Ph.D. in Computer Science from the University of Wisconsin-Madison. Prior to pursuing Ph.D. work, Hao spent three years working as a developer for IBM.
Annie Malkus, Ph.D.
Imaging Developer
Annie joined HealthMyne in 2018. She is working on making more and more useful metrics. Her prior work includes academic research experience from nuclear physics like modeling neutrino oscillations in accretion disks to imaging techniques like hyperpolarized gas diffusion in lung MRI. Annie has a Ph.D. in Physics from the University of Wisconsin-Madison.
Mark Gehring
Senior Technology Advisor & Co-Founder
Prior to joining HealthMyne, Mark was a co-founder and President of Propeller Health (formerly Asthmapolis), a respiratory disease management company that employs sensors to track adherence and measure patient response to treatment. Previously Mark was a co-founder and CEO of two medical imaging companies that are also relevant to HealthMyne. Geometrics developed the Pinnacle 3D radiation treatment planning system which has had dominant market share worldwide since the mid 90’s and is now sold by Philips Medical Systems. Pinnacle has been used to plan approximately 25% of the radiation treatments worldwide since 1996. UltraVisual developed a web-based, 3D-enabled PACS used by radiologists to diagnostically read images and by clinicians to view images at large hospitals and hospital networks. UltraVisual merged with another startup, Emageon, and reached over $100 million in sales, and executed a successful IPO on Nasdaq in 2005
Gary Wendt, MD, MBA
Dr. Wendt is a professor of Radiology at the University of Wisconsin-Madison and vice-chair of Informatics. The UW Health radiology network which he oversees is one of the largest in the world consisting of 70 radiologists, over 2000 physicians, and 700,000 exams managed per year.
Dr. Wendt is board-certified in diagnostic radiology and specializes in neuroradiology. He has served as an advisor to many HCIT companies including McKesson, Vital Images and UltraVisual. He is a renowned expert in the field of advancing medical imaging technology to improve imaging quality and patient outcome. Dr. Wendt received an M.D. from the Medical College of Wisconsin and an MBA from the University of Wisconsin-Madison. He has co-authored over 30 publications and has over 50 invited presentations.
Robert J. Gillies, Ph.D.
Dr. Gillies received his PhD in Zoology from UC Davis in 1979. After a post-doctoral appointment at Yale University (1979-1982), he has held faculty positions at Colorado State Univ. (1982-1988), the Univ. of Arizona (1988-2008) and the Moffitt Cancer Center (2008-pres), where he is chair of the Department of Cancer Imaging and Metabolism, vice-chair of Radiology and director of the Center of Excellence in Imaging and Technology.
He has published over 243 peer-reviewed articles in the use of imaging and spectroscopy to interrogate tumor physiology, and is currently PI or co-PI on eight NCI grants or sub-contracts focused on cancer imaging. He has a long-standing interest in detailed image analysis to better describe tumor physiology and, in 2009, he coined the term “Radiomics”. He has been a major contributor to this field ever since, primarily in improved diagnosis of lung and prostate cancer.
Peter Hoban, Ph.D.
Peter has a 25 year background in the radiation oncology area, including academic, clinical and industry-based roles. Before joining HealthMyne he was VP of Research and Product Management at Xcision Medical Systems, a startup company commercializing a breast cancer radiosurgery system. Peter held marketing and product management positions at TomoTherapy (acquired by Accuray) for nine years prior to this. After obtaining his Ph.D. in Medical Physics from the University of Waikato, in his native New Zealand, Peter spent ten years as a research scientist and clinical physicist in Australia. Highlights of his career include mentoring graduate students and participating in the development and clinical validation of innovative technologies.
